{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:28:23Z","timestamp":1787164103185,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Graduate Student Innovation Ability Training project of Hebei University of Science and Technology","award":["XJCXZZSS202307"],"award-info":[{"award-number":["XJCXZZSS202307"]}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2024208001"],"award-info":[{"award-number":["H2024208001"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2020208018"],"award-info":[{"award-number":["H2020208018"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["C2020208023"],"award-info":[{"award-number":["C2020208023"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81760750"],"award-info":[{"award-number":["81760750"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shijiazhuang Key R&D and SME Innovation Program: Special Program for Biopharmaceutical Key Technology Innovation","award":["241200253A"],"award-info":[{"award-number":["241200253A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10495-026-02373-4","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:19:46Z","timestamp":1785133186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT\/CD155 signal axis"],"prefix":"10.1007","volume":"31","author":[{"given":"Yachan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgen","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yike","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zining","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"2373_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438\u2013451. https:\/\/doi.org\/10.3322\/caac.21583","journal-title":"CA Cancer J Clin"},{"key":"2373_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2373_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast Cancer Treatment: Rev JAMA 321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"Breast Cancer Treatment: Rev JAMA"},{"key":"2373_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ctrv.2009.10.001","volume":"36","author":"Y Fern\u00e1ndez","year":"2010","unstructured":"Fern\u00e1ndez Y, Cueva J, Palomo AG et al (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36:33\u201342. https:\/\/doi.org\/10.1016\/j.ctrv.2009.10.001","journal-title":"Cancer Treat Rev"},{"key":"2373_CR5","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.drudis.2020.07.006","volume":"25","author":"H Zhu","year":"2020","unstructured":"Zhu H, Du C, Yuan M et al (2020) PD-1\/PD-L1 Counterattack alliance: multiple strategies for treating triple-negative breast cancer. Drug Discov Today 25:1762\u20131771. https:\/\/doi.org\/10.1016\/j.drudis.2020.07.006","journal-title":"Drug Discov Today"},{"key":"2373_CR6","doi-asserted-by":"publisher","first-page":"111436","DOI":"10.1016\/j.biopha.2021","volume":"138","author":"P Lotfinejad","year":"2021","unstructured":"Lotfinejad P, Kazemi T, Safaei S et al (2021) Pd-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomed Pharmacother 138:111436. https:\/\/doi.org\/10.1016\/j.biopha.2021","journal-title":"Biomed Pharmacother"},{"key":"2373_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW et al (2019) Mechanisms controlling PD-L1 expression in cancer. Mol Cell 76:359\u2013370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030","journal-title":"Mol Cell"},{"key":"2373_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al R, Abosy et al (2019) Subsets of exhausted CD8\u2009+\u2009T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20:326\u2013336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6","journal-title":"Nat Immunol"},{"key":"2373_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14737140.2018.1458613","volume":"18","author":"G Griguolo","year":"2018","unstructured":"Griguolo G, Dieci MV, Guarneri V et al (2018) Olaparib for the treatment of breast cancer. Expert Rev Anticancer Ther 18:519\u2013530. https:\/\/doi.org\/10.1080\/14737140.2018.1458613","journal-title":"Expert Rev Anticancer Ther"},{"key":"2373_CR10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A, Inhibitors PARP (2017) Synthetic lethality in the clinic. Science 355:1152\u20131158. https:\/\/doi.org\/10.1126\/science.aam7344","journal-title":"Science"},{"key":"2373_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation. N Engl J Med 377:523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"key":"2373_CR12","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","volume":"12","author":"T Cascone","year":"2021","unstructured":"Cascone T, Weissferdt A, Godoy MCB et al (2021) Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12:5045. https:\/\/doi.org\/10.1038\/s41467-021-25188-0","journal-title":"Nat Commun"},{"key":"2373_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.it.2018.10.009","volume":"39","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zheng P (2018) How does an anti-CTLA-4 antibody promote cancer immunity? Trends Immunol 39:953\u2013956. https:\/\/doi.org\/10.1016\/j.it.2018.10.009","journal-title":"Trends Immunol"},{"key":"2373_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41422-018-0031-9","volume":"28","author":"J Pol","year":"2018","unstructured":"Pol J, Kroemer G, Kroemer (2018) Anti-CTLA-4 Immunotherapy: uncoupling toxicity and efficacy. Cell Res 28:501\u2013502. https:\/\/doi.org\/10.1038\/s41422-018-0031-9","journal-title":"Cell Res"},{"key":"2373_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C (2020) TIGIT as an emerging immune checkpoint. Clin Exp Immunol 200:108\u2013119. https:\/\/doi.org\/10.1111\/cei.13407","journal-title":"Clin Exp Immunol"},{"key":"2373_CR16","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8:e000957. https:\/\/doi.org\/10.1136\/jitc-2020-000957","journal-title":"J Immunother Cancer"},{"key":"2373_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/d41573-021-00123-6","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) Immuno-oncology target TIGIT attracts a new contender. Nat Rev Drug Discov 20:576. https:\/\/doi.org\/10.1038\/d41573-021-00123-6","journal-title":"Nat Rev Drug Discov"},{"key":"2373_CR18","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/annonc\/mdn291","volume":"19","author":"RS Finn","year":"2008","unstructured":"Finn RS (2008) Targeting Src in breast cancer. Ann Oncol 19:1379\u20131386. https:\/\/doi.org\/10.1093\/annonc\/mdn291","journal-title":"Ann Oncol"},{"key":"2373_CR19","doi-asserted-by":"publisher","first-page":"e21064","DOI":"10.1038\/onc.2008.250","volume":"6","author":"S Zheng","year":"2011","unstructured":"Zheng S, Chang S, Lu J et al (2011) Characterization Of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS ONE 6:e21064. https:\/\/doi.org\/10.1038\/onc.2008.250","journal-title":"PLoS ONE"},{"key":"2373_CR20","doi-asserted-by":"publisher","unstructured":"Green TP, Fennell M, Whittaker R et al (2009) Whittaker, preclinical anticancer activity of the potent, oral src inhibitor AZD0530. Mol Oncol. 3, 248\u2009\u2013\u200961. https:\/\/doi.org\/10.1016\/j.molonc.2009.01.002","DOI":"10.1016\/j.molonc.2009.01.002"},{"key":"2373_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2021.08.030","volume":"521","author":"HY Lim","year":"2021","unstructured":"Lim HY, Ong PS, Wang L et al (2021) Celastrol in cancer therapy: recent developments, challenges and prospects. Cancer Lett 521:252\u2013267. https:\/\/doi.org\/10.1016\/j.canlet.2021.08.030","journal-title":"Cancer Lett"},{"key":"2373_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.001","volume":"515","author":"B Ren","year":"2021","unstructured":"Ren B, Kwah MX, Liu C et al (2021) Resveratrol for cancer therapy: challenges and future perspectives. Cancer Lett 515:63\u201372. https:\/\/doi.org\/10.1016\/j.canlet.2021.05.001","journal-title":"Cancer Lett"},{"key":"2373_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"L Sleire","year":"2017","unstructured":"Sleire L, F\u00f8rde HE, Netland IA et al (2017) Netland, drug repurposing in cancer. Pharmacol Res 124:74\u201391. https:\/\/doi.org\/10.1016\/j.phrs.2017.07.013","journal-title":"Pharmacol Res"},{"key":"2373_CR24","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","volume":"10","author":"V Parvathaneni","year":"2019","unstructured":"Parvathaneni V, Kulkarni NS, Muth A et al (2019) Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov 10:2076\u20132085. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.014","journal-title":"Drug Discov"},{"key":"2373_CR25","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cam4.2108","volume":"8","author":"Y Xiang","year":"2019","unstructured":"Xiang Y, Guo Z, Zhu P et al (2019) Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med 8:1958\u20131975. https:\/\/doi.org\/10.1002\/cam4.2108","journal-title":"Cancer Med"},{"key":"2373_CR26","doi-asserted-by":"publisher","unstructured":"Liu J, Guo Y, Cao J (2020) Matrine triggers colon cancer cell apoptosis and G0\/G1 cell cycle arrest via mediation of microrna-22. Phytother Res 34:1619\u20131628 https:\/\/doi.org\/10.1002\/ptr.6626","DOI":"10.1002\/ptr.6626"},{"key":"2373_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/ijc.31947","volume":"144","author":"A Hesari","year":"2019","unstructured":"Hesari A, Azizian M, Sheikhi A, Sheikhi et al (2019) Chemopreventive and therapeutic potential of curcumin in esophageal cancer: current and future status. Int J Cancer 144:1215\u20131226. https:\/\/doi.org\/10.1002\/ijc.31947","journal-title":"Int J Cancer"},{"key":"2373_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jconrel.2019.01.016","volume":"296","author":"Y Qu","year":"2019","unstructured":"Qu Y, Chu B, Wei X et al (2019) Redox\/Ph Dual-stimuli responsive camptothecin prodrug nanogels for on-demand drug delivery. J Control Release 296:93\u2013106. https:\/\/doi.org\/10.1016\/j.jconrel.2019.01.016","journal-title":"J Control Release"},{"key":"2373_CR29","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","volume":"26","author":"P Narayan","year":"2020","unstructured":"Narayan P, Wahby S, Gao JJ et al (2020) FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res 26:2284\u20132289. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3545","journal-title":"Clin Cancer Res"},{"key":"2373_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","volume":"29","author":"S Krishna","year":"2008","unstructured":"Krishna S, Bustamante L, Haynes RK et al (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29:520\u2013527. https:\/\/doi.org\/10.1016\/j.tips.2008.07.004","journal-title":"Trends Pharmacol Sci"},{"key":"2373_CR31","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1002\/jcp.24086","volume":"227","author":"C Zhou","year":"2012","unstructured":"Zhou C, Pan W, Wang XP et al (2012) Artesunate induces apoptosis via a bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J Cell Physiol 227:3778\u20133786. https:\/\/doi.org\/10.1002\/jcp.24086","journal-title":"J Cell Physiol"},{"key":"2373_CR32","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1080\/15384047.2015.1071738","volume":"16","author":"B Wang","year":"2015","unstructured":"Wang B, Hou D, Liu Q et al (2015) Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol Ther 16:1548\u20131556. https:\/\/doi.org\/10.1080\/15384047.2015.1071738","journal-title":"Cancer Biol Ther"},{"key":"2373_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phymed.2018.09.178","volume":"54","author":"C Hagens","year":"2019","unstructured":"Hagens C, Walter-Sack I, Goeckenjan M et al (2019) Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33\/2). Phytomedicine 54:140\u2013148. https:\/\/doi.org\/10.1016\/j.phymed.2018.09.178","journal-title":"Phytomedicine"},{"key":"2373_CR34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/cmdc.202000174","volume":"15","author":"T Fr\u00f6hlich","year":"2020","unstructured":"Fr\u00f6hlich T, Mai C, Bogautdinov RP et al (2020) Synthesis of tamoxifen-artemisinin and estrogen-artemisinin hybrids highly potent against breast and prostate cancer. ChemMedChem 15:1473\u20131479. https:\/\/doi.org\/10.1002\/cmdc.202000174","journal-title":"ChemMedChem"},{"key":"2373_CR35","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1371\/journal.pone.0021064","volume":"27","author":"YM Chang","year":"2008","unstructured":"Chang YM, Bai L, Liu S et al (2008) Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27:6365\u20136375. https:\/\/doi.org\/10.1371\/journal.pone.0021064","journal-title":"Oncogene"},{"key":"2373_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpharm.2013.12.040","volume":"462","author":"J Lin","year":"2014","unstructured":"Lin J, Wang X, Wu Q et al (2014) Development of salvianolic acid B-tanshinone II A-glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells. Int J Pharm 462:11\u201318. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.12.040","journal-title":"Int J Pharm"},{"issue":"1","key":"2373_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","volume":"22","author":"M Huang","year":"2024","unstructured":"Huang M, Yu X, Wang Q et al (2024) The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8\u2009+\u2009T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling. Cell Commun Signal 22(1):35. https:\/\/doi.org\/10.1186\/s12964-023-01455-z","journal-title":"Cell Commun Signal"},{"key":"2373_CR38","doi-asserted-by":"publisher","first-page":"1096341","DOI":"10.3389\/fonc.2023.1096341","volume":"13","author":"QD Xia","year":"2023","unstructured":"Xia QD, Li B, Sun JX et al (2023) Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. Front Oncol 13:1096341. https:\/\/doi.org\/10.3389\/fonc.2023.1096341","journal-title":"Front Oncol"},{"key":"2373_CR39","doi-asserted-by":"publisher","first-page":"215830","DOI":"10.1016\/j.canlet.2022.215830","volume":"545","author":"M Zhan","year":"2022","unstructured":"Zhan M, Zhao X, Zhang Y et al (2022) CD155 in tumor progression and targeted therapy. Cancer Lett 545:215830. https:\/\/doi.org\/10.1016\/j.canlet.2022.215830","journal-title":"Cancer Lett"},{"issue":"1","key":"2373_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-020-00913-2","volume":"13","author":"KB Lupo","year":"2020","unstructured":"Lupo KB, Matosevic S (2020) CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J Hematol Oncol 13(1):76. https:\/\/doi.org\/10.1186\/s13045-020-00913-2","journal-title":"J Hematol Oncol"},{"issue":"22","key":"2373_CR41","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1186\/s13045-020-00913-2","volume":"77","author":"W He","year":"2017","unstructured":"He W, Zhang H, Han F et al (2017) CD155T\/TIGIT signaling regulates CD8+T-cell metabolism and promotes tumor progression in human gastric Cancer CD155\/TIGIT regulates T-cell metabolism in gastric Cancer. Cancer Res 77(22):6375\u20136388. https:\/\/doi.org\/10.1186\/s13045-020-00913-2","journal-title":"Cancer Res"},{"issue":"10","key":"2373_CR42","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/cas.13324","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Zheng Q, Xin N et al (2017) CD155, an onco-immunologic molecule in human tumors. Cancer Sci 108(10):1934\u20131938. https:\/\/doi.org\/10.1111\/cas.13324","journal-title":"Cancer Sci"},{"issue":"1","key":"2373_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu X, Gu Z et al (2024) Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res 12(1):7. https:\/\/doi.org\/10.1186\/s40364-023-00543-z","journal-title":"Biomark Res"},{"key":"2373_CR44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.imlet.2017.08.010","volume":"190","author":"TO Robinson","year":"2017","unstructured":"Robinson TO, Schluns KS (2017) The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett 190:159\u2013168. https:\/\/doi.org\/10.1016\/j.imlet.2017.08.010","journal-title":"Immunol Lett"},{"issue":"8","key":"2373_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6(8):595\u2013601. https:\/\/doi.org\/10.1038\/nri1901","journal-title":"Nat Rev Immunol"},{"issue":"228","key":"2373_CR46","doi-asserted-by":"publisher","first-page":"228ra37","DOI":"10.1126\/scitranslmed.3007240","volume":"6","author":"B Mlecnik","year":"2014","unstructured":"Mlecnik B, Bindea G, Angel HK et al (2014) Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 6(228):228ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3007240","journal-title":"Sci Transl Med"},{"issue":"5","key":"2373_CR47","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.xcrm.2024.101531","volume":"5","author":"W Shi","year":"2024","unstructured":"Shi W, Liu N, Liu Z et al (2024) Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Rep Med 5(5):101531. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101531","journal-title":"Cell Rep Med"},{"issue":"10","key":"2373_CR48","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu, J (2022) Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol 43(10):833\u2013847. https:\/\/doi.org\/10.1016\/j.it.2022.08.004","journal-title":"Trends Immunol"},{"issue":"1","key":"2373_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"3","author":"KC Conlon","year":"2015","unstructured":"Conlon KC, Lugli E, Welles HC et al (2015) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 3(1):74\u201382. https:\/\/doi.org\/10.1200\/JCO.2014.57.3329","journal-title":"J Clin Oncol"},{"issue":"8","key":"2373_CR50","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00262-019-02372-2","volume":"68","author":"A Pinette","year":"2019","unstructured":"Pinette A, McMichael E, Courtney NB et al (2019) An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 68(8):1379\u20131389. https:\/\/doi.org\/10.1007\/s00262-019-02372-2","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2373_CR51","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cac2.12311","volume":"42","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhang Q, Yang N et al (2022) Crosstalk between IL-15R\u03b1+ tumor-associated macrophages and breast cancer cells reduces CD8+ T cell recruitment. Cancer Commun (Lond) 42(6):536\u2013557. https:\/\/doi.org\/10.1002\/cac2.12311","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"2373_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-018-0265-1","volume":"20","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhang Y, Yi P et al (2019) The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells. Nat Immunol 20(1):10\u201317. https:\/\/doi.org\/10.1038\/s41590-018-0265-1","journal-title":"Nat Immunol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02373-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02373-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02373-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:31Z","timestamp":1787162551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02373-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2373"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02373-4","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mouse experiments were performed according to the Guide for the Care and Use of Laboratory Animals and approved by Hebei University of Science and Technology Institutional Review Board.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"199"}}